Terns Pharmaceuticals, Inc.
TERN
Updated: 23/09/2026, 21:08:43
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
No summaries found.
- Share price
- $52.95
- Market cap
- $4.77B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Amy L. Burroughs
- Employees
- 59
- IPO date
- 05/02/2021
- Beta
- -0.38
- Last dividend
- $0.00
- Day range
- $52.95 – $52.97
- 52-week range
- $2.66 – $53.19
- 1-day performance
- -0.03%
- 1-year performance
- 1894.35%
- Current drawdown (1Y)
- -0.45%
- CIK
- 0001831363
- CUSIP
- 880881107
- ISIN
- US8808811074
- Created
- 07/12/2025, 14:31:59
- Last update
- 23/09/2026, 21:08:43
Track Terns Pharmaceuticals, Inc. with an AI analyst
See which prediction-market events move TERN, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Tern shares surge as it ups stakes in AI health services company Talking Medicines
Proactive Investors • STOCK • 26/05/2026, 08:18:55
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia
GlobeNewsWire • STOCK • 27/04/2026, 10:05:00
Why Terns Pharmaceuticals Stock Rocked the Market in March
The Motley Fool • STOCK • 08/04/2026, 16:00:57
Shareholder Alert: Ademi LLP investigates whether Terns Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
GlobeNewsWire • STOCK • 07/04/2026, 08:52:00
Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN
Business Wire • STOCK • 25/03/2026, 22:59:00
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
PRNewsWire • STOCK • 25/03/2026, 14:30:00
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
GlobeNewsWire • STOCK • 25/03/2026, 07:48:00
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Business Wire • STOCK • 25/03/2026, 07:45:00
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally
The Motley Fool • STOCK • 16/03/2026, 20:53:19
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing
The Motley Fool • STOCK • 20/02/2026, 01:02:22